Suvorexant Inversely Affects Phosphorylated Tau in Human Cerebrospinal Fluid and Plasma
- 1University of Minnesota Medical School
Abstract
Alzheimer disease (AD) is characterized by amyloid-{beta} plaques and neurofibrillary tangles of tau. Suvorexant, a dual orexin receptor antagonist, was previously shown to acutely reduce the ratio of phosphorylated tau-181 to unphosphorylated tau-181 (pT181/T181) in cerebrospinal fluid (CSF). However, its effects on plasma pT181/T181 and broader proteomic networks remain unknown. Here, we conducted a secondary analysis of samples from a randomized, placebo-controlled trial of 25 participants receiving placebo or suvorexant 20 mg. Paired CSF and plasma samples were collected longitudinally via indwelling intrathecal and intravenous catheters. Plasma AD biomarkers were quantified by mass spectrometry, and proteomic profiling was performed using the SomaScan 11K assay on samples from hours 0, 16, and 24. Suvorexant increased pT181/T181 in plasma while decreasing it in CSF between 08:00 to 16:00. At the pathway level, suvorexant increased the extracellular abundance of proteins associated with translation, RNA binding, cytoskeletal organization and endosomal sorting, centrally at 16 hours and peripherally at 24 hours, and decreased cytokine and receptor-ligand signaling and serine protease activity in plasma at 24 hours. As plasma biomarkers are increasingly used for clinical screening and trial enrollment, factors that influence their levels, including medications, must be identified and their effects on interpretation understood.
Related
- Amyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention
- Multi‐platform comparison of plasma phosphorylated tau assays: analytical and workflow factors drive clinical implementation decisions
- Telephone-administered semantic fluency task in older adults without dementia in relation to in-person testing and plasma phosphorylated tau-217
- Comparative Detection of IDH1 R132H and TERT Promoter Mutations in Plasma and Cerebrospinal Fluid of Patients with Glioma Using Targeted Droplet Digital PCR
- Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid
BibTeX
@misc{pedersen2026suvorexant,
title = {{Suvorexant Inversely Affects Phosphorylated Tau in Human Cerebrospinal Fluid and Plasma}},
author = {T. J. Pedersen and J. Yu and A. Li and L. Ibanez and O. M. Bubu and B. P. Lucey},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.03.26367196},
url = {https://www.medrxiv.org/content/10.64898/2026.11.03.26367196v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Suvorexant Inversely Affects Phosphorylated Tau in Human Cerebrospinal Fluid and Plasma
AU - T. J. Pedersen
AU - J. Yu
AU - A. Li
AU - L. Ibanez
AU - O. M. Bubu
AU - B. P. Lucey
PY - 2026
DA - 2026/11/03
PB - medRxiv
DO - 10.64898/2026.11.03.26367196
UR - https://www.medrxiv.org/content/10.64898/2026.11.03.26367196v1
AB - Alzheimer disease (AD) is characterized by amyloid-{beta} plaques and neurofibrillary tangles of tau. Suvorexant, a dual orexin receptor antagonist, was previously shown to acutely reduce the ratio of phosphorylated tau-181 to unphosphorylated tau-181 (pT181/T181) in cerebrospinal fluid (CSF). However, its effects on plasma pT181/T181 and broader proteomic networks remain unknown. Here, we conducted a secondary analysis of samples from a randomized, placebo-controlled trial of 25 participants receiving placebo or suvorexant 20 mg. Paired CSF and plasma samples were collected longitudinally via indwelling intrathecal and intravenous catheters. Plasma AD biomarkers were quantified by mass spectrometry, and proteomic profiling was performed using the SomaScan 11K assay on samples from hours 0, 16, and 24. Suvorexant increased pT181/T181 in plasma while decreasing it in CSF between 08:00 to 16:00. At the pathway level, suvorexant increased the extracellular abundance of proteins associated with translation, RNA binding, cytoskeletal organization and endosomal sorting, centrally at 16 hours and peripherally at 24 hours, and decreased cytokine and receptor-ligand signaling and serine protease activity in plasma at 24 hours. As plasma biomarkers are increasingly used for clinical screening and trial enrollment, factors that influence their levels, including medications, must be identified and their effects on interpretation understood.
ER -